Translational blocks in hypofractionated radiation therapy (HRT) combined with immunotherapy

The most impressive clinical outcome was found when we use HRT or immunotherapy as individual treatment, although, the clinical research in the combination of both modalities is still premature. In this regard, a number of barriers might experience by exercising Sung et al. model, in which several blocks can be identified. Regulatory burden, Practice limitation, and lack of funding may consider as the root cause of delaying implementation of such combination. However, careful examination of other “blocks” would move such clinical research more rapidly.

Biography :

Mohammed Y Almaghrabi is a currently working as Radiation Oncologist at King Abdullah Medical City, Saudi Arabia. He is leading Stereotactic RadioSurgery/Stereotactic Body Radiation Therapy task groups at the same Hospital. He is a CNS tumour board Chairman. He was the Head of Radiation Oncology department at Prince Faisal Cancer Centre, Saudi Arabia. He holds his Research experience from University of Ottawa Canada and Nantes University, France. He has been a recipient of many awards and grants. He was selected as a Sectional Editor (Radiation Oncology, Biomarkers) for Journal of Cancer Treatment and Diagnosis, Reviewer for British Journal of Radiology and CARO annual scientific meeting. His research experience includes various programs, contributions and participation in different countries for diverse fields of study.

E-mail: almagrabimd@hotmail.com

PDF HTML